Smith, T.J., Hillner, B.E., Schmitz, N., Linch, D.C., Dreger, P., Goldstone, A.H., Boogaerts, M.A., Ferrant, A., Link, H., Zander, A., Yanovich, S., Kitchin, R. and Erder, M.H. (1997) Economic analysis of a randomized clinical trial to compare filgrastrim-mobilized peripheral-blood progenitor cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Journal of Clinical Oncolology, 15(1), 5-10.

has been cited by the following article:

• TITLE: Hematopoietic stem cells from peripheral blood the perspective of non-mobilized peripheral blood

  AUTHORS: Vassilios Katsares, Zissis Paparidis, Eleni Nikolaidou, Anastasia Petsa, Iliana Karvounidou, Karina-Alina Ardelean, Nikolaos Peroulis, Nikolaos Grigoriadis, John Grigoriadis

  KEYWORDS: Non-Mobilized Peripheral Blood;Hematopoietic Stem Cells; Ex Vivo Expansion

  JOURNAL NAME: Health, Vol.2 No.6, June 28, 2010

  ABSTRACT: The peripheral blood is a major source of hematopoietic stem cells. Almost for two decades the peripheral blood has been mobilized, in order to enhance the CD34+ concentration. The isolated stem cells from the mobilized peripheral blood are used as an alternative, or in addition to bone marrow derived stem cells. In this paper, a new perspective is being discussed; the use of non-mobilized peripheral blood as an alternative source for hematopoietic progenitor cells. The number of isolated hematopoietic stem cells is evaluated using flow cytometry. The viability can be evaluated using the trypan blue exclusion test, the flow cytometry or automated assays. The isolated hematopoietic stem cells could be used for ex vivo expansion either in static systems or in proper bioreactor systems, prior to cryopreservation and/or transplantation.